Abstract
Adeno-associated virus (AAV) vectors are promising human gene delivery vehicles due to their ability to establish long-term gene expression in a wide variety of target tissues; however, the broad native viral tropism raises concerns over the feasibility and safety of their systemic administration. To overcome this issue, much effort has been made to redirect AAVs toward specific tissues. This review presents several design strategies that have been applied to generate AAVs that target specific tissues and cells while inhibiting the transduction of non-target tissues. Multiple methods of vector capsid engineering have shown promise in vitro, including indirect targeting by adaptor systems and direct targeting by the insertion of antibodies or receptor-specific small peptide motifs. Other strategies, including creating mosaic or chimeric capsids and directed evolution, have also been used to successfully retarget AAV vectors. This research will further expand the clinical applications of AAV vectors by enhancing the control over tissue-specific gene delivery.
Keywords: Adeno-assocaited virus, capsid, human gene delivery, serotype, targeting, tropism.
Current Pharmaceutical Design
Title:Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy
Volume: 21 Issue: 22
Author(s): Yarong Liu, Natnaree Siriwon, Jennifer A. Rohrs and Pin Wang
Affiliation:
Keywords: Adeno-assocaited virus, capsid, human gene delivery, serotype, targeting, tropism.
Abstract: Adeno-associated virus (AAV) vectors are promising human gene delivery vehicles due to their ability to establish long-term gene expression in a wide variety of target tissues; however, the broad native viral tropism raises concerns over the feasibility and safety of their systemic administration. To overcome this issue, much effort has been made to redirect AAVs toward specific tissues. This review presents several design strategies that have been applied to generate AAVs that target specific tissues and cells while inhibiting the transduction of non-target tissues. Multiple methods of vector capsid engineering have shown promise in vitro, including indirect targeting by adaptor systems and direct targeting by the insertion of antibodies or receptor-specific small peptide motifs. Other strategies, including creating mosaic or chimeric capsids and directed evolution, have also been used to successfully retarget AAV vectors. This research will further expand the clinical applications of AAV vectors by enhancing the control over tissue-specific gene delivery.
Export Options
About this article
Cite this article as:
Liu Yarong, Siriwon Natnaree, Rohrs A. Jennifer and Wang Pin, Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy, Current Pharmaceutical Design 2015; 21 (22) . https://dx.doi.org/10.2174/1381612821666150531171653
DOI https://dx.doi.org/10.2174/1381612821666150531171653 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MEET THE GUEST EDITOR [Hot Topic: Modern Omics-Based Platform for High Throughput Screening for Novel Drug Targets (Part 2) (Guest Editor: Canhua Huang)]
Combinatorial Chemistry & High Throughput Screening Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Natural Products, Synthetic and Non-Nucleoside Compounds as Inhibitors of Enzymes Related to DNA: Update 2013
Current Enzyme Inhibition (Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening Epigenetic Regulators Governing Cancer Stem Cells and Epithelial- Mesenchymal Transition in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment
Current Cancer Drug Targets Computer Aided Drug Design: Success and Limitations
Current Pharmaceutical Design Recent Advances of Graphene-based Hybrids with Magnetic Nanoparticles for Biomedical Applications
Current Medicinal Chemistry Anti-Tumor Activity of Non-Nucleosidic Reverse Transcriptase Inhibitors
Current Pharmaceutical Design The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry Lamellarins, from A to Z: A Family of Anticancer Marine Pyrrole Alkaloids
Current Medicinal Chemistry - Anti-Cancer Agents Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets Benzophenone Sulfonamide Derivatives as Interacting Partners and Inhibitors of Human P-glycoprotein
Anti-Cancer Agents in Medicinal Chemistry Melatonin Treatment Combined with TGF-β Silencing Inhibits Epithelial- Mesenchymal Transition in CF41 Canine Mammary Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma
Current Gene Therapy